Published in J Immunol on January 01, 1977
Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes. J Clin Invest (1980) 6.61
Bactericidal and bacteriolytic activity of serum against gram-negative bacteria. Microbiol Rev (1983) 5.73
Vwa+ phenotype of Yersinia enterocolitica. Infect Immun (1983) 3.72
The key role of peptidoglycan in the opsonization of Staphylococcus aureus. J Clin Invest (1978) 2.83
Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood (2007) 2.72
Lipid A and resistance of Salmonella typhimurium to antimicrobial granule proteins of human neutrophil granulocytes. Infect Immun (1984) 2.41
The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum. J Clin Invest (1978) 2.37
Neutrophil-mediated injury to endothelial cells. Enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest (1986) 2.22
Biological activities of Brucella abortus lipopolysaccharides. Infect Immun (1981) 2.13
Interaction of lipopolysaccharides with plasma high-density lipoprotein in rats. Infect Immun (1980) 1.85
Activation of human THP-1 cells and rat bone marrow-derived macrophages by Helicobacter pylori lipopolysaccharide. Infect Immun (1995) 1.74
C1q binding and activation of the complement classical pathway by Klebsiella pneumoniae outer membrane proteins. Infect Immun (1993) 1.72
Role of Escherichia coli K capsular antigens during complement activation, C3 fixation, and opsonization. Infect Immun (1979) 1.68
Composition and antigenic activity of the oligosaccharide moiety of Haemophilus influenzae type b lipooligosaccharide. Infect Immun (1985) 1.62
Antibody-independent interaction of the first component of complement with Gram-negative bacteria. Infect Immun (1978) 1.60
Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3. J Exp Med (1985) 1.57
Role of lipopolysaccharide in opsonization and phagocytosis of Pseudomonas aeruginosa. Infect Immun (1985) 1.54
A high-molecular-weight fraction of smooth lipopolysaccharide in Klebsiella serotype O1:K20 contains a unique O-antigen epitope and determines resistance to nonspecific serum killing. Infect Immun (1989) 1.45
C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med (1993) 1.45
Influence of a deficiency of the second component of complement on the bactericidal activity of neutrophils in vitro. J Clin Invest (1977) 1.44
Antibody-independent binding of the first component of complement (C1) and its subcomponent C1q to the S and R forms of Salmonella minnesota. Infect Immun (1981) 1.43
Haemophilus influenzae type b lipooligosaccharide: stability of expression and association with virulence. Infect Immun (1987) 1.38
Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol (2002) 1.33
Activation of complement by opportunist pathogens and chemotypes of Salmonella minnesota. Infect Immun (1977) 1.32
Activation of complement system by porins extracted from Salmonella typhimurium. Infect Immun (1984) 1.31
Role for endotoxin in the leukocyte infiltration accompanying Escherichia coli inflammation. Infect Immun (1982) 1.29
Mitogen-activated protein kinases and nuclear factor-kappaB regulate Helicobacter pylori-mediated interleukin-8 release from macrophages. Biochem J (2002) 1.27
Phenolic glycolipid-1 of Mycobacterium leprae binds complement component C3 in serum and mediates phagocytosis by human monocytes. J Exp Med (1991) 1.27
Role of lipopolysaccharide and complement in susceptibility of Haemophilus ducreyi to human serum. Infect Immun (1985) 1.27
Correlation between the production of extracellular substances by type III group B streptococcal strains and virulence in a mouse model. Infect Immun (1981) 1.24
Macrophage stimulation by bacterial lipopolysaccharides. II. Evidence for differentiation signals delivered by lipid A and by a protein rich fraction of lipopolysaccharides. J Exp Med (1978) 1.22
Differential complement activation and susceptibility to human serum bactericidal action by Vibrio species. Infect Immun (1983) 1.20
Immunobiological activities of synthetic lipid A analogs and related compounds as compared with those of bacterial lipopolysaccharide, re-glycolipid, lipid A, and muramyl dipeptide. Infect Immun (1983) 1.19
Role of lipopolysaccharide and complement in susceptibility of Klebsiella pneumoniae to nonimmune serum. Infect Immun (1987) 1.16
The effect of complement depletion on bacterial lipopolysaccharide (LPS)-induced hemodynamic and hematologic changes in the Rhesus monkey. Am J Pathol (1978) 1.14
Activation of the alternative pathway of complement by mycobacteria and cord factor. Infect Immun (1980) 1.14
Activation of the alternative pathway of complement by Entamoeba histolytica. Clin Exp Immunol (1978) 1.13
Clinical application of a new nephelometric technique to measure complement activation. J Clin Pathol (1983) 1.13
Enhancement of platelet response to immune complexes and IgG aggregates by lipid A-rich bacterial lipopolysaccharides. J Exp Med (1978) 1.12
Role of complement in lethal bacterial lipopolysaccharide-induced hypotensive and coagulative changes. Infect Immun (1978) 1.11
Biological effects of the interaction of staphylococcal alpha-toxin with human serum. Infect Immun (1982) 1.11
Antiinflammatory effects of endotoxin. Inhibition of rabbit polymorphonuclear leukocyte responses to complement (C5)-derived peptides in vivo and in vitro. Am J Pathol (1983) 1.10
Interaction between complement subcomponent C1q and the Klebsiella pneumoniae porin OmpK36. Infect Immun (1996) 1.06
Distinct microenvironmental cues stimulate divergent TLR4-mediated signaling pathways in macrophages. Sci Signal (2016) 1.05
Aeromonas salmonicida resistance to complement-mediated killing. Infect Immun (1994) 1.05
Lipopolyamines: novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother (1999) 1.05
Killing of the S and Re forms of Salmonella minnesota via the classical pathway of complement activation in guinea-pig and human sera. Immunology (1980) 1.05
The third component of complement protects against Escherichia coli endotoxin-induced shock and multiple organ failure. J Exp Med (1994) 1.04
Comparison of different vaccines and induced immune response against Campylobacter jejuni colonization in the infant mouse. Epidemiol Infect (1989) 1.02
Mechanisms of lipopolysaccharide-initiated rabbit platelet responses: alternative complement pathway dependence of the lytic response. Infect Immun (1978) 1.01
Distribution of endotoxin (lipopolysaccharide) in the tissues of lipopolysaccharide-responsive and -unresponsive mice. Infect Immun (1978) 1.01
Requirements of immunoglobulin and the classical and alternative complement pathways for phagocytosis and intracellular killing of multiple strains of Gram-negative aerobic bacilli. Infect Immun (1979) 0.99
Mesophilic Aeromonas sp. serogroup O:11 resistance to complement-mediated killing. Infect Immun (1996) 0.99
Endotoxaemia and complement activation in acute pancreatitis in man. Gut (1982) 0.99
Interaction of lipopolysaccharides and lipid A with complement in rats and its relation to endotoxicity. Infect Immun (1978) 0.99
Antibody-independent activation of the classical pathway of human serum complement by lipid A is restricted to re-chemotype lipopolysaccharide and purified lipid A. Infect Immun (1986) 0.99
Complement activation and C3 binding by serum-sensitive and serum-resistant strains of Pseudomonas aeruginosa. Infect Immun (1989) 0.97
Induction of human granulocyte chemiluminescence by bacterial lipopolysaccharides. Infect Immun (1987) 0.97
Inhibition of chemotaxis of neutrophil leukocytes to interleukin-8 by endotoxins of various bacteria. Infect Immun (1991) 0.96
Lipopolysaccharide phase variation determines the complement-mediated serum susceptibility of Coxiella burnetii. Infect Immun (1988) 0.95
Enhanced phagocytosis and bactericidal activity of hepatic reticuloendothelial system during endotoxin tolerance. Infect Immun (1980) 0.93
Neutrophil adherence induced by lipopolysaccharide in vitro. Role of plasma component interaction with lipopolysaccharide. J Clin Invest (1992) 0.93
Human complement activation by lipopolysaccharides from bacteroides oralis, fusobacterium nucleatum, and veillonella parvula. Infect Immun (1979) 0.93
Interaction of platelets with bacterial endotoxins. Agents Actions (1983) 0.92
The distribution of lipopolysaccharide in normocomplementemic and C3-depleted rabbits and rhesus monkeys. Am J Pathol (1980) 0.90
Complement activation and complement-dependent inflammation by Neisseria meningitidis are independent of lipopolysaccharide. Infect Immun (2004) 0.89
Antibody-independent interaction between the first component of human complement, C1, and the outer membrane of Escherichia coli D31 m4. Biochem J (1985) 0.86
Immunological activities of Capnocytophaga cellular components. Infect Immun (1982) 0.85
Sensitivity of Capnocytophaga species to bactericidal properties of human serum. Infect Immun (1985) 0.85
In vitro evaluation of the action of irrigating solutions associated with intracanal medications on Escherichia coli and its endotoxin in root canals. J Appl Oral Sci (2011) 0.84
Anticomplementary activity of tuberculin: relationship to platelet aggregation and lytic response. Infect Immun (1979) 0.83
Electron microscopic study showing antibody-independent binding of C1q, a subcomponent of the first component of complement, to serum-sensitive salmonellae. Infect Immun (1984) 0.83
Growth-supporting activity of fragment Ba of the human alternative complement pathway for activated murine B lymphocytes. J Exp Med (1986) 0.82
Binding of mannose-binding protein to Klebsiella O3 lipopolysaccharide possessing the mannose homopolysaccharide as the O-specific polysaccharide and its relation to complement activation. Infect Immun (1995) 0.82
Vibrio anguillarum resistance to rainbow trout (Oncorhynchus mykiss) serum: role of O-antigen structure of lipopolysaccharide. Infect Immun (1999) 0.81
Bactericidal effect of normal swine sera on Treponema hyodysenteriae. Infect Immun (1986) 0.81
Complement activation by whole endotoxin is blocked by a monoclonal antibody to factor B. Infect Immun (1994) 0.81
Characterization of the susceptibility of Pseudomonas aeruginosa to complement-mediated killing: role of antibodies to the rough lipopolysaccharide on serum-sensitive strains. Infect Immun (1988) 0.80
Interaction between complement subcomponent C1q and bacterial lipopolysaccharides. Biochem J (1989) 0.80
Production of thermophilic actinomycete-hay aerosols for use in experimental hypersensitivity pneumonitis. Appl Environ Microbiol (1977) 0.79
Enteric vascular endothelial response to bacterial endotoxin. Int J Exp Pathol (1993) 0.79
Opsonic requirements for phagocytosis of Legionella micdadei by polymorphonuclear leukocytes. Infect Immun (1985) 0.78
In vitro and in vivo changes in human complement caused by silage. Environ Health Perspect (1986) 0.78
Inhibition of polymorphonuclear leucocyte functions in vivo by Yersinia enterocolitica lipopolysaccharide. Ann Rheum Dis (1989) 0.78
Endotoxins release histamine by complement activation and potentiate bacteria-induced histamine release. Agents Actions (1986) 0.78
Circulating immune complexes and complement C3 and C4 levels in a selected group of patients with rhinitis in Lebanon. Clin Mol Allergy (2004) 0.77
Local skin response in mice induced by a single intradermal injection of bacterial lipopolysaccharide and lipid A. Infect Immun (1991) 0.76
Detection of Pseudomonas aeruginosa antigenemia in granulocytopenic rabbits by radiommunoassay. J Clin Microbiol (1980) 0.76
Lipid A dependence of the ocular response to circulating endotoxin in rabbits. Infect Immun (1980) 0.76
Biochemical mechanisms of lipid-A-mediated enhancement of platelet secretory responses to aggregated immunoglobulins. Am J Pathol (1981) 0.75
Complement activating factor(s) of Trypanosoma lewisi: some physiochemical characteristics of the active components. Can J Comp Med (1978) 0.75
Appearance of specific antibody-bearing cells in human bronchial mucosa after local immunization with bacterial vaccine. J Clin Microbiol (1986) 0.75
C5L2, the Second C5a Anaphylatoxin Receptor, Suppresses LPS-Induced Acute Lung Injury. Am J Respir Cell Mol Biol (2016) 0.75
Participation of endotoxin in root canal infections: A systematic review and meta-analysis. Eur J Dent (2017) 0.75
Endotoxins and disease mechanisms. Annu Rev Med (1987) 6.07
The effects of bacterial endotoxins on host mediation systems. A review. Am J Pathol (1978) 6.03
Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry (1976) 5.43
Fractions of lipopolysaccharide from Escherichia coli O111:B4 prepared by two extraction procedures. J Biol Chem (1975) 4.80
Bacterial endotoxins and host immune responses. Adv Immunol (1979) 4.50
Immunologic properties of bacterial lipopolysaccharide (LPS): correlation between the mitogenic, adjuvant, and immunogenic activities. J Immunol (1975) 3.18
Isolation of a lipid A bound polypeptide responsible for "LPS-initiated" mitogenesis of C3H/HeJ spleen cells. J Exp Med (1976) 2.88
Mothers as behavior therapists for their own children. Behav Res Ther (1965) 2.86
Relationship of the structure of bacterial lipopolysaccharides to its function in mitogenesis and adjuvanticity. Proc Natl Acad Sci U S A (1973) 2.61
Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. J Exp Med (1979) 2.39
Stimulation of a T-independent primary anti-hapten response in vitro by TNP-lipopolysaccharide (TNP-LPS). J Immunol (1975) 2.30
Immunologic properties of bacterial lipopolysaccharide (LPS). II. The unresponsiveness of C3H/HeJ Mouse spleen cells to LPS-induced mitogenesis is dependent on the method used to extract LPS. J Exp Med (1975) 2.22
An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide. J Biol Chem (1997) 2.17
Dissociation between mitogenicity and immunogenicity of TNP-lipopolysaccharide, a T-independent antigen. J Exp Med (1975) 2.10
Mediation systems in bacterial lipopolysaccharide-induced hypotension and disseminated intravascular coagulation. I. The role of complement. J Exp Med (1975) 1.91
Specific endotoxic lipopolysaccharide-binding receptors on murine splenocytes. III. Binding specificity and characterization. J Immunol (1991) 1.86
Lipopolysaccharide nomenclature--past, present, and future. J Bacteriol (1986) 1.80
Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med (1974) 1.74
Specific endotoxic lipopolysaccharide-binding proteins on murine splenocytes. I. Detection of lipopolysaccharide-binding sites on splenocytes and splenocyte subpopulations. J Immunol (1988) 1.73
Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b. J Immunol (1980) 1.65
Synthesis and biochemical characterization of a photoactivatable, iodinatable, cleavable bacterial lipopolysaccharide derivative. J Biol Chem (1985) 1.64
Inhibition of the mitogenic response to lipopolysaccharide (LPS) in mouse spleen cells by polymyxin B. J Immunol (1977) 1.57
Lipopolysaccharide-induced selective priming effects on tumor necrosis factor alpha and nitric oxide production in mouse peritoneal macrophages. J Exp Med (1993) 1.57
Binding and activation of the first component of human complement by the lipid A region of lipopolysaccharides. J Immunol (1978) 1.53
Inhibition of lipopolysaccharide-initiated activation of serum complement by polymyxin B. Infect Immun (1976) 1.53
The pulmonary vascular sequestration of neutrophils in endotoxemia is initiated by an effect of endotoxin on the neutrophil in the rabbit. Am Rev Respir Dis (1987) 1.52
Lipid A-dependent lymphocyte proliferation in "endotoxin-nonresponder" mice. Rev Infect Dis (1984) 1.49
Specific endotoxic lipopolysaccharide-binding proteins on murine splenocytes. II. Membrane localization and binding characteristics. J Immunol (1988) 1.43
Cutting edge: bacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages. J Immunol (1999) 1.39
Bacterial endotoxins and pathogenesis. Rev Infect Dis (1983) 1.33
Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol (1993) 1.30
Reprogramming of lipopolysaccharide-primed macrophages is controlled by a counterbalanced production of IL-10 and IL-12. J Immunol (1998) 1.30
Studies on membrane synthesis in Bacillus megaterium KM. J Mol Biol (1970) 1.30
Activation of rat mast cells by low molecular weight stimuli. J Immunol (1974) 1.28
An in vitro line of the B cell tumor BCL1 can be activated by LPS to secrete IgM1. J Immunol (1980) 1.25
Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia. Antimicrob Agents Chemother (1995) 1.25
Stimulation of T-independent antibody responses by hapten-lipopolysaccharides without repeating polymeric structure. Infect Immun (1979) 1.24
Conversion of lipopolysaccharides to molecular aggregates with reduced subunit heterogeneity: demonstration of LPS-responsiveness in "endotoxin-unresponsive" C3H/HeJ splenocytes. J Immunol (1983) 1.24
Macrophage stimulation by bacterial lipopolysaccharides. II. Evidence for differentiation signals delivered by lipid A and by a protein rich fraction of lipopolysaccharides. J Exp Med (1978) 1.22
Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha through a post-transcriptional mechanism. J Immunol (2001) 1.21
Commercial preparations of lipoteichoic acid contain endotoxin that contributes to activation of mouse macrophages in vitro. Infect Immun (2001) 1.21
Interleukin-6 production by endothelial cells via stimulation of protease-activated receptors is amplified by endotoxin and tumor necrosis factor-alpha. J Interferon Cytokine Res (2001) 1.17
Differential expression of caveolin-1 in lipopolysaccharide-activated murine macrophages. Infect Immun (2000) 1.17
Activation of human serum complement by bacterial lipopolysaccharides: structural requirements for antibody independent activation of the classical and alternative pathways. Mol Immunol (1987) 1.16
Pertussis toxin-sensitive factor differentially regulates lipopolysaccharide-induced tumor necrosis factor-alpha and nitric oxide production in mouse peritoneal macrophages. J Immunol (1993) 1.16
Lipopolysaccharide interaction with lysozyme. Binding of lipopolysaccharide to lysozyme and inhibition of lysozyme enzymatic activity. J Biol Chem (1989) 1.16
Identification and characterization of lipopolysaccharide-binding proteins on human peripheral blood cell populations. Infect Immun (1992) 1.12
Endotoxic-lipopolysaccharide-specific binding proteins on lymphoid cells of various animal species: association with endotoxin susceptibility. Infect Immun (1989) 1.12
Endotoxin-cell-membrane interactions leading to transmembrane signaling. Contemp Top Mol Immunol (1981) 1.11
Hydrazine sulfate protects D-galactosamine-sensitized mice against endotoxin and tumor necrosis factor/cachectin lethality: evidence of a role for the pituitary. J Exp Med (1991) 1.09
Lactoferrin-lipopolysaccharide interactions. Effect on lactoferrin binding to monocyte/macrophage-differentiated HL-60 cells. J Immunol (1991) 1.08
Lipopolysaccharide structure-function relationship in activation versus reprogramming of mouse peritoneal macrophages. J Leukoc Biol (1993) 1.07
Necessity and sufficiency of beta interferon for nitric oxide production in mouse peritoneal macrophages. Infect Immun (1994) 1.07
The fate of E. coli lipopolysaccharide after the uptake of E. coli by murine macrophages in vitro. J Immunol (1984) 1.07
Promoting low-fat entree choices in a public cafeteria. J Appl Behav Anal (1986) 1.06
The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing. J Immunol (1986) 1.06
Low-dose lipopolysaccharide (LPS) pretreatment of mouse macrophages modulates LPS-dependent interleukin-6 production in vitro. Infect Immun (1996) 1.06
Lipid A as the biologically active moiety in bacterial endotoxin (LPS)-initiated generation of procoagulant activity by peripheral blood leukocytes. Blood (1977) 1.05
Lipopolyamines: novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother (1999) 1.05
Serum-dependent and -independent effects of bacterial lipopolysaccharides on human neutrophil oxidative capacity in vitro. J Reticuloendothel Soc (1982) 1.04
Effect of lipid A-associated protein and lipid A on the expression of lipopolysaccharide activity. I. Immunological activity. Immunology (1980) 1.03
Altered regulation of inducible nitric oxide synthase expression in macrophages from senescent mice. Infect Immun (1996) 1.01
Modeling of T cell contact-dependent B cell activation. IL-4 and antigen receptor ligation primes quiescent B cells to mobilize calcium in response to Ia cross-linking. J Immunol (1991) 1.01
Distribution of endotoxin (lipopolysaccharide) in the tissues of lipopolysaccharide-responsive and -unresponsive mice. Infect Immun (1978) 1.01
Mechanisms of lipopolysaccharide-initiated rabbit platelet responses: alternative complement pathway dependence of the lytic response. Infect Immun (1978) 1.01
Chemical and biologic properties of a protein-rich fraction of bacterial lipopolysaccharides. I. The in vitro murine lymphocyte response. J Immunol (1977) 1.01
Modulation of endotoxin lethality in mice by hydrazine sulfate. Infect Immun (1989) 1.01
Two functionally independent pathways for lipopolysaccharide-dependent activation of mouse peritoneal macrophages. J Immunol (1997) 1.00
Immunologic activity of lipopolysaccharides released from macrophages after the uptake of intact E. coli in vitro. J Immunol (1986) 1.00
The selective binding of aggregated IgG to lipid A-rich bacterial lipopolysaccharides. J Immunol (1978) 0.99
Activation of C3H/HeJ macrophage tumoricidal activity and cytokine release by R-chemotype lipopolysaccharide preparations. Differential effects of IFN-gamma. J Immunol (1990) 0.99
Anticomplementary activity of lipid A isolated from lipopolysaccharides. Proc Soc Exp Biol Med (1973) 0.98
Generation and characterization of hamster-mouse hybridomas secreting monoclonal antibodies with specificity for lipopolysaccharide receptor. J Immunol (1990) 0.97
Differences in therapeutic efficacy among cell wall-active antibiotics in a mouse model of gram-negative sepsis. J Infect Dis (1995) 0.97
What are the microbial components implicated in the pathogenesis of sepsis? Report on a symposium. Clin Infect Dis (2000) 0.96
CD14 is not involved in Rhodobacter sphaeroides diphosphoryl lipid A inhibition of tumor necrosis factor alpha and nitric oxide induction by taxol in murine macrophages. Infect Immun (1995) 0.95
Tumor necrosis factor-alpha gene expression in the tissues of normal mice. Cytokine (1992) 0.94
The interaction of Escherichia coli with normal human serum: factors affecting the capacity of serum to mediate lipopolysaccharide release. Microb Pathog (1988) 0.94
Stimulation of peritoneal cell arginase by bacterial lipopolysaccharides. Am J Pathol (1980) 0.94
Evidence for lipopolysaccharide as the predominant proinflammatory mediator in supernatants of antibiotic-treated bacteria. Infect Immun (1994) 0.93
Mechanism of polymyxin B-mediated lysis of lipopolysaccharide-treated erythrocytes. Infect Immun (1985) 0.92
Selective interaction between lymphocytes and lipid A subunits in lipopolysaccharide macromolecular aggregates. Rev Infect Dis (1984) 0.92
The physical-chemical characterization and biologic activity of serum released lipopolysaccharides. J Immunol (1988) 0.92
Activation of murine spleen cells by lipid A: negative modulation of lipid A mitogenic activity by O-antigen polysaccharide. J Immunol (1985) 0.92
Evidence for different requirements in physical state for the interaction of lipopolysaccharides with the classical and alternative pathways of complement. Eur J Biochem (1982) 0.92
Dissociation of anticomplementary and adjuvant properties of proteins derived from cobra venom. Immunology (1976) 0.92
Induction of macrophage-mediated tumor cytotoxicity by a hamster monoclonal antibody with specificity for lipopolysaccharide receptor. J Immunol (1990) 0.91
Chemical and biological properties of a protein-rich fraction of bacterial lipopolysaccharides. II. The in vitro rat peritoneal mast cell response. J Immunol (1977) 0.90
Lipopolysaccharide/lipid A receptors on lymphocytes and macrophages. Int Rev Immunol (1990) 0.90
Possible alteration of normal mechanisms of endotoxin toxicity in vivo by actinomycin D. J Infect Dis (1982) 0.90
Cytotoxic activity and production of toxic nitrogen oxides by macrophages treated with IFN-gamma and monoclonal antibodies against the 73-kDa lipopolysaccharide receptor. J Immunol (1992) 0.89
Immunostimulation of C3H/HeJ lymphoid cells by R-chemotype lipopolysaccharide preparations. J Immunol (1989) 0.89
Characterization of specific binding of a human immunoglobulin M monoclonal antibody to lipopolysaccharide and its lipid A domain. Infect Immun (1993) 0.89
Lipopolysaccharide receptors and signal transduction pathways in mononuclear phagocytes. Curr Top Microbiol Immunol (1992) 0.89
Selective association of lipid-rich R-like lipopolysaccharide subunits with murine spleen cells. Mol Immunol (1984) 0.88
In vivo biological activities of endotoxin. Prog Clin Biol Res (1985) 0.88
Protection of C3H/HeJ mice from lethal Salmonella typhimurium LT2 infection by immunization with lipopolysaccharide-lipid A-associated protein complexes. Infect Immun (1986) 0.87
Isolation of a macrophage-like cell line defective in binding of lipopolysaccharide. Influence of serum and lipopolysaccharide chain length on macrophage activation. J Immunol (1993) 0.87